Harvard Bioscience Inc. announced that its board has approved the spinoff of the company’s wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology Inc., known as HART. Harvard Bioscience will not own any shares of HART, which will be an independent public company. Harvard Bioscience makes a broad range of tools to advance life science research and regenerative medicine.